siRNA-based nanocarriers for targeted drug delivery to control breast cancer
Sumel Ashique, Basmah Almohaywi, Nazima Haider, Sabina Yasmin, Afzal Hussain, Neeraj Mishra, Ashish Garg
Abstract
Breast cancer is a challenging health issue in women and the second-leading cause of mortality around world. In this review, we addressed beneficial role of siRNA to control breast cancer. Various limitations of siRNA based therapeutic approaches, innate challenges siRNA delivery, in vitro and in vivo findings have been highlighted to focus recent advancement to control breast cancer. The current approaches and comparative assessment against conventional chemotherapeutics methods have been thoroughly investigated for the conclusive outcomes. Various nanocomposites and nanomedicines with or without surface functionalization have played a major role for convincing impact of siRNA delivery for anticipated therapeutic efficacy by stabilization and protecting bio-active siRNA in in-vitro and in-vivo condition. Various targeted genes for siRNA knockdown were reported to control breast cancer by tuning its biological performance in nanocarrier systems. Conclusively, siRNA loaded nanocarriers are promising option to control breast cancer compared to conventional (druggable) and mAbs (monoclonal antibodies) based therapy.